Graves' Disease
Graves' disease is an autoimmune disorder that causes the thyroid gland to become overactive, leading to symptoms such as weight loss, rapid heartbeat, and anxiety.
Graves' Disease: Rilzabrutinib Study
We are investigating whether rilzabrutinib can help reduce thyroid activity in adults with Graves' disease. The study also aims to evaluate the safety of this new treatment.
3-6 months11-15 visitsEfficacy phase (II)No PlaceboPartially RemoteInvestigational MedicinesOralEndocrinologyInternal Medicine
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have a confirmed diagnosis of Graves' disease with active hyperthyroidism?
- Do you have active Graves' orbitopathy, as confirmed by an eye exam?
- Have you had any history of hyperthyroidism not caused by Graves' disease?
- Have you experienced any sight-threatening symptoms related to Graves' orbitopathy in the last 6 months?
- Have you had symptoms of Graves' orbitopathy for more than 9 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Rilzabrutinib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitaetsklinikum Essen AöR
Klinik für Endokrinologie, Diabetologie und Stoffwechsel
Essen, Germany
Universitaetsklinikum Frankfurt AöR
Zentrum Der Inneren Medizin Medizinische Klinik I
Frankfurt am Main, Germany
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Milan, Italy
Sponsor: Sanofi-Aventis Recherche & Developpement
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.